<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[pharmaceutical company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/pharmaceutical+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to pharmaceutical company]]></description>
	<s:counts start="0" returned="20" found="1457" />
	<language>en-us</language>
	<item>
		<title><![CDATA[FDA Seeks Advice From Blogger; Google Solves Pharma's Ad Problems]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005281/fda-seeks-advice-from-blogger-google-solves-pharmas-ad-problems/]]></link>
		<description><![CDATA[The FDA sought the advice of John Mack, a blogger with 20,000 monthly readers who runs the Pharma Marketing Blog, on how drug companies should use the web to advertise their products. The agency usually likes to hear from lawyers, drug company executives and academics when it seeks regulatory advice....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 12 Nov 2009 15:08:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/advice.html"><![CDATA[Advice]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/blogger.html"><![CDATA[Blogger]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">GOOG</category>
	</item>
	<item>
		<title><![CDATA[Roll up for Japan's medical mystery tour]]></title>
		<link><![CDATA[http://www.bnet.com/2468-13071_23-361133.html]]></link>
		<description><![CDATA[ Outside the sumo ring, obesity is not the most pressing problem in generally snake-hipped Japan. It is thus symbolic of Japan's pharmaceutical industry that Takeda should this week have struck a deal with Amylin Pharmaceuticals, a US biotechnology firm, to develop fat-busting medicines whose main markets will be in...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 04 Nov 2009 18:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/japan.html"><![CDATA[Japan]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/takeda.html"><![CDATA[Takeda]]></category>
		<category domain="http://resources.bnet.com/topic/daiichi+sankyo.html"><![CDATA[Daiichi Sankyo]]></category>
		<category domain="http://resources.bnet.com/topic/cost-containment.html"><![CDATA[Cost-containment]]></category>
		<category domain="http://resources.bnet.com/topic/general+news.html"><![CDATA[General News]]></category>
		<category domain="http://resources.bnet.com/topic/health+%2526+healthcare.html"><![CDATA[Health & Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
	</item>
	<item>
		<title><![CDATA[WebMD HLTH Corporation Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14061_23-360511.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions.  Our first question comes from Mark Mahaney with Citigroup. Mark Mahaney &#8211; Citigroup On the materiality on both the UK launch and the pets vertical, the pets offering, anyway to help us think about how big that can be, what kind of margin...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 03 Nov 2009 20:41:08 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/channel.html"><![CDATA[Channel]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/webmd.html"><![CDATA[WebMD]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/hlth+corp..html"><![CDATA[HLTH Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">HLTH</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WBMD</category>
		<category domain="tickers">HLTH,WBMD</category>
	</item>
	<item>
		<title><![CDATA[Unemployed Drug Reps: "Go East, Young Man (and Women)"]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004986/unemployed-drug-reps-go-east-young-man-and-women/]]></link>
		<description><![CDATA[Pharmaceutical sales reps: Are you sick of seeing headlines about layoffs at virtually every major pharma company? Wish you could turn the clock back to when every company was hiring and new reps could name their price? Now you can -- if you're willing to live in Japan. by Jim...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 28 Oct 2009 10:12:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/women.html"><![CDATA[Women]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/gender+and+diversity.html"><![CDATA[Gender And Diversity]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Covance Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-355411.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. We'll take our first question today from Mr. Greg Bolan with Wells Fargo. Greg Bolan - Wells Fargo Just thinking about Early Development activity these days and I realize this is an overly simplistic analogy, but it would appear to me that pharma has been...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 22 Oct 2009 11:19:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/wells+fargo+%2526+co..html"><![CDATA[Wells Fargo & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/covance+inc..html"><![CDATA[Covance Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/joe+herring+lumpy.html"><![CDATA[Joe Herring Lumpy]]></category>
		<category domain="http://resources.bnet.com/topic/managed+hosting.html"><![CDATA[Managed Hosting]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/it+operations.html"><![CDATA[It Operations]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing+%2526+subcontracting.html"><![CDATA[Outsourcing & Subcontracting]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CVD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WFC</category>
		<category domain="tickers">CVD,WFC</category>
	</item>
	<item>
		<title><![CDATA[AptarGroup Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14049_23-353106.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator Instructions Our first question comes from Ghansham Panjabi - RW Baird. Ghansham Panjabi - RW Baird Would you give us some color on intra quarter volume trajectory across all three businesses please, Beauty & Home, Closures and Pharma? Steve Hagge When you are talking intra...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 15 Oct 2009 11:08:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/inventory.html"><![CDATA[Inventory]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/quarter.html"><![CDATA[Quarter]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/aptargroup+inc..html"><![CDATA[AptarGroup Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ATR</category>
		<category domain="tickers">ATR</category>
	</item>
	<item>
		<title><![CDATA[Pharma on Twitter: J&J Tweets the Most; Novartis Has Most Followers, Abbott Not Out of the Gate Yet]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004749/pharma-on-twitter-j-novartis-has-most-followers-abbott-not-out-of-the-gate-yet/]]></link>
		<description><![CDATA[InTouch Solutions, a pharma marketing agency, has produced a handy grid listing all the top pharma company Twitter streams and offering some stats on each one. Boehringer Ingelheim and Novartis are the oldest tweeters, but Johnson & Johnson has Twittered the most -- 419 posts, by the InTouch count. by...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 12 Oct 2009 09:33:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/twitter+inc..html"><![CDATA[Twitter Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">JNJ,NVS</category>
	</item>
	<item>
		<title><![CDATA[Obama's Speech Offers Lucrative New Universe for Big Pharma]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004212/obamas-speech-offers-lucrative-new-universe-for-big-pharma/]]></link>
		<description><![CDATA[President Obama's speech on Wednesday night laid down clear battle lines in the healthcare reform debate: drug companies are on Obama's side, health insurers and Republicans are on the other. It will be interesting to see who has the more powerful lobbyists, Big Pharma or Big Managed Care. by Jim...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 11 Sep 2009 08:26:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/barack+obama.html"><![CDATA[Barack Obama]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/obama.html"><![CDATA[Obama]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare+reform.html"><![CDATA[Healthcare Reform]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Generic Threat to Optimer Pharma's Fidaxomicin Antibiotic]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003960/generic-threat-to-optimer-pharmas-fidaxomicin-antibiotic/]]></link>
		<description><![CDATA[The relative efficacy of Optimer Pharma's investigational antibiotic, fidaxomicin, compared to standard-of-care vancomycin marketed as Vancocin by drugmaker ViroPharma, remains unclear. Even if Optimer obtains regulatory approval to market fidaxomicin, its commercial success will be limited by the likely appearance of generic vancomycin. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 28 Aug 2009 12:08:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/antibiotic.html"><![CDATA[Antibiotic]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
	</item>
	<item>
		<title><![CDATA[Daiichi Sankyo Company Limited: Business Transformation Maintains Momentum Towards High Performance]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=1181161]]></link>
		<description><![CDATA[Daiichi Sankyo Company Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. To maintain its momentum toward high performance, Daiichi Sankyo knew that it needed...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Thu, 27 Aug 2009 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/accenture+ltd..html"><![CDATA[Accenture Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/high-performance.html"><![CDATA[High-performance]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/daiichi+sankyo+company+ltd..html"><![CDATA[Daiichi Sankyo Company Ltd.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACN</category>
		<category domain="tickers">ACN</category>
	</item>
	<item>
		<title><![CDATA[Simcere Pharmaceutical Group Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F156859-simcere-pharmaceutical-group-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Simcere Pharmaceutical Group SCR   Q2 2009 Earnings Call   August 18, 2009 8:00 am ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 18 Aug 2009 11:42:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
	</item>
	<item>
		<title><![CDATA[Simcere Pharmaceutical Group Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-332582.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Shaojing Tong. Shaojing Tong - Bank of America-Merrill Lynch I just want to focus on this brand generic portfolio, whose sales fall substantially lower than the average normal level. You explained somewhat, but my focus was beyond...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 18 Aug 2009 10:42:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
	</item>
	<item>
		<title><![CDATA[Emerging market for medicines]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F4d3e7cd6-808e-11de-bf04-00144feabdc0.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ When Haruo Naito, chief executive of Eisai, the Japanese pharmaceutical company, signalled his continued interest in western markets by inaugurating his company's European headquarters in the UK last month, his mind was already elsewhere."We have already finished our investments in all major areas in the US and Europe," he...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 03 Aug 2009 19:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/india.html"><![CDATA[India]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/emerging+market.html"><![CDATA[Emerging Market]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
	</item>
	<item>
		<title><![CDATA[WebMD Health Corporation Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14052_23-326932.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you, sir. Operator Instructions Our first question comes from Mark Mahaney from Citigroup. Please go ahead. Mark Mahaney &#8211; Citigroup  Great. Thank you. I wanted to ask a question about some of the impact on your business on customer demand from some of the regulatory...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 30 Jul 2009 18:26:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advertisement.html"><![CDATA[Advertisement]]></category>
		<category domain="http://resources.bnet.com/topic/brand.html"><![CDATA[Brand]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/webmd+health+corp..html"><![CDATA[WebMD Health Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/webmd.html"><![CDATA[WebMD]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WBMD</category>
		<category domain="tickers">WBMD</category>
	</item>
	<item>
		<title><![CDATA[Waters Corporation Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-325701.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions  Your first question comes from Tycho Peterson &#8211; JP Morgan Securities. Tycho Peterson &#8211; JP Morgan Securities I&#8217;m wondering if you can kind of elaborate on your pharma comments around ACQUITY.  You&#8217;ve talked in the past about standardization, I&#8217;m wondering if...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 28 Jul 2009 11:26:25 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/waters+corp..html"><![CDATA[Waters Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WAT</category>
		<category domain="tickers">JPM,WAT</category>
	</item>
	<item>
		<title><![CDATA[Sigma-Aldrich Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-324169.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. The question-and-answer session will be conduct electronically. Operator Instructions. We will take our first question from Quintin Lai at Baird. Quintin Lai - R.W. Baird Hi, good morning and good evening, Rakesh. Rakesh Sachdev Good evening. Quintin Lai - R.W. Baird Jai, could you kind...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 23 Jul 2009 20:09:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/account.html"><![CDATA[Account]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/baird.html"><![CDATA[Baird]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/singapore+airlines.html"><![CDATA[Singapore Airlines]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SIAL</category>
		<category domain="tickers">SIAL</category>
	</item>
	<item>
		<title><![CDATA[Time for Big Pharma to Place Some Bets on Obesity?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003196/time-for-big-pharma-to-place-some-bets-on-obesity/]]></link>
		<description><![CDATA[All three of the leading biotech drugs for obesity remain unpartnered. Orexigen's Phase III program is now complete, and Arena and Vivus should have final Phase III data this quarter...so how long is big pharma going to wait? by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 20 Jul 2009 21:20:03 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/orexigen.html"><![CDATA[Orexigen]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Lobbying Money: Who's Spending What Fighting Healthcare Reform]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002798/pharma-lobbying-money-whos-spending-what-fighting-healthcare-reform/]]></link>
		<description><![CDATA[As President Obama waits for Congress to deliver a heathcare reform bill, pharmaceutical companies are spending millions on lobbyists to thwart any measure that might make drug prices cheaper or even allow the government to negotiate them, according to the Center for Responsive Politics.  Companies spent 41 percent more...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 22 Jun 2009 10:01:26 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare+reform.html"><![CDATA[Healthcare Reform]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Judge Rules Schering Employees' Anonymous Posts on Cafe Pharma Can Be Used as Evidence]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002523/judge-rules-schering-employees-anonymous-posts-on-cafe-pharma-can-be-used-as-evidence/]]></link>
		<description><![CDATA[A New Jersey federal judge has ruled that anonymous postings on Cafe Pharma can be used as evidence in a lawsuit over whether Schering-Plough knew the results of its Vytorin study would be negative and hid them for months in an attempt to mislead shareholders. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 04 Jun 2009 08:31:13 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/evidence.html"><![CDATA[Evidence]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[ASGT: A Reminder That Pharma Doesn't Want to See You Cured]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002439/asgt-a-reminder-that-pharma-doesnt-want-to-see-you-cured/]]></link>
		<description><![CDATA[Pharma and biotech companies are less interested in cures and more interested in medications that require a lifetime of administration, according to scientists at last week's annual meeting of the American Society of Gene Therapy. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 01 Jun 2009 16:31:50 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
	</item>
</channel>
</rss>
